TITLE

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

AUTHOR(S)
Pope, Whitney; Qiao, Xin; Kim, Hyun; Lai, Albert; Nghiemphu, Phioanh; Xue, Xi; Ellingson, Benjamin; Schiff, David; Aregawi, Dawit; Cha, Soonmee; Puduvalli, Vinay; Wu, Jing; Yung, Wai-Kwan; Young, Geoffrey; Vredenburgh, James; Barboriak, Dan; Abrey, Lauren; Mikkelsen, Tom; Jain, Rajan; Paleologos, Nina
PUB. DATE
July 2012
SOURCE
Journal of Neuro-Oncology;Jul2012, Vol. 108 Issue 3, p491
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We have tested the predictive value of apparent diffusion coefficient (ADC) histogram analysis in stratifying progression-free survival (PFS) and overall survival (OS) in bevacizumab-treated patients with recurrent glioblastoma multiforme (GBM) from the multi-center BRAIN study. Available MRI's from patients enrolled in the BRAIN study ( n = 97) were examined by generating ADC histograms from areas of enhancing tumor on T1 weighted post-contrast images fitted to a two normal distribution mixture curve. ADC classifiers including the mean ADC from the lower curve (ADC-L) and the mean lower curve proportion (LCP) were tested for their ability to stratify PFS and OS by using Cox proportional hazard ratios and the Kaplan-Meier method with log-rank test. Mean ADC-L was 1,209 × 10mm/s ± 224 (SD), and mean LCP was 0.71 ± 0.23 (SD). Low ADC-L was associated with worse outcome. The hazard ratios for 6-month PFS, overall PFS, and OS in patients with less versus greater than mean ADC-L were 3.1 (95 % confidence interval: 1.6, 6.1; P = 0.001), 2.3 (95 % CI: 1.3, 4.0; P = 0.002), and 2.4 (95 % CI: 1.4, 4.2; P = 0.002), respectively. In patients with ADC-L <1,209 and LCP >0.71 versus ADC-L >1,209 and LCP <0.71, there was a 2.28-fold reduction in the median time to progression, and a 1.42-fold decrease in the median OS. The predictive value of ADC histogram analysis, in which low ADC-L was associated with poor outcome, was confirmed in bevacizumab-treated patients with recurrent GBM in a post hoc analysis from the multi-center (BRAIN) study.
ACCESSION #
76350886

 

Related Articles

  • The role of STAT3 in tumor-mediated immune suppression. Ferguson, Sherise; Srinivasan, Visish; Heimberger, Amy // Journal of Neuro-Oncology;Jul2015, Vol. 123 Issue 3, p385 

    The role of tumor-induced immune modulation in cancer progression is currently a focus of investigation. The signal transducer and activator of transcription 3 (STAT3) is an established molecular hub of immunosuppression, and its signaling pathways are classically overactivated within...

  • Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival? Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi // Journal of Neuro-Oncology;May2008, Vol. 88 Issue 1, p105 

    Abstract  In this study, the records of 276 adult patients with recurrent glioblastoma (GBM) treated at recurrence at our institution between 2004 and 2006 were reviewed for progression-free survival (PFS), overall survival (OS), and toxicity. At recurrence, all patients underwent systemic...

  • Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. Rahman, Rifaquat; Hamdan, Alhafidz; Zweifler, Rebecca; Jiang, Han; Norden, Andrew; Reardon, David; Mukundan, Srinivasan; Wen, Patrick; Huang, Raymond // Journal of Neuro-Oncology;Aug2014, Vol. 119 Issue 1, p149 

    While patients with recurrent glioblastoma receiving anti-angiogenic therapy demonstrate significant response rates, the benefit on patient survival is less clear. We assessed whether histogram analysis of diffusion weighted MRI can stratify for progression-free and overall survival. Baseline...

  • Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patientcohort. Scholtyssek, Felix; Zwiener, Isabella; Schlamann, Annika; Seidel, Clemens; Meixensberger, Jürgen; Bauer, Manfred; Hoffmann, Karl-Titus; Combs, Stephanie E.; von Bueren, André O.; Kortmann, Rolf-Dieter; Müller, Klaus // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Purposes: First, to evaluate outcome, the benefit of concurrent chemotherapy and prognostic factors in a cohort of sixty-four high-grade glioma patients who underwent a second course of radiation therapy at progression. Second, to validate a new prognostic score for overall survival after...

  • Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. Mandel, Jacob; Yust-Katz, Shlomit; Cachia, David; Wu, Jimin; Liu, Diane; de Groot, John; Yung, Alfred; Gilbert, Mark // Journal of Neuro-Oncology;Dec2014, Vol. 120 Issue 3, p597 

    There are few studies reporting the incidence of leptomeningeal dissemination (LMD) in patients with glioblastoma; only small case series have been published. Consequently, there are no established standards of care for these patients. Therefore, we undertook this retrospective review to...

  • Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. Hamza, Mohamed; Mandel, Jacob; Conrad, Charles; Gilbert, Mark; Yung, W.; Puduvalli, Vinay; DeGroot, John // Journal of Neuro-Oncology;Aug2014, Vol. 119 Issue 1, p135 

    Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma. It is not known if there are differences in outcome between early versus delayed BEV treatment of recurrent glioblastoma. We examined the relationship between the time of starting BEV treatment and outcomes...

  • Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Szkandera, J; Absenger, G; Liegl-Atzwanger, B; Pichler, M; Stotz, M; Samonigg, H; Glehr, M; Zacherl, M; Stojakovic, T; Gerger, A; Leithner, A // British Journal of Cancer;4/30/2013, Vol. 108 Issue 8, p1677 

    Background:Recent data indicate that tumour microenvironment, which is influenced by inflammatory cells, has a crucial role in cancer progression and clinical outcome of patients. In the present study, we investigated the prognostic relevance of preoperative neutrophil/lymphocyte (N/L) ratio on...

  • Outcomes and Prognostic Factors of 251 Patients with Minimally Invasive Follicular Thyroid Carcinoma. Sugino, Kiminori; Kameyama, Kaori; Ito, Koichi; Nagahama, Mitsuji; Kitagawa, Wataru; Shibuya, Hiroshi; Ohkuwa, Keiko; Yano, Yukiko; Uruno, Takashi; Akaishi, Junko; Suzuki, Akifumi; Masaki, Chie; Ito, Kunihiko // Thyroid;Aug2012, Vol. 22 Issue 8, p798 

    Background: Radioiodine ablation after total thyroidectomy is the generally accepted treatment for patients with widely invasive follicular thyroid carcinoma (FTC). The therapeutic strategy for minimally invasive FTC, on the other hand, is still a matter of controversy. The histological...

  • A model checking method for the proportional hazards model with recurrent gap time data. Huang, Chiung-Yu; Luo, Xianghua; Follmann, Dean A. // Biostatistics;Jul2011, Vol. 12 Issue 3, p535 

    Recurrent events are the natural outcome in many medical and epidemiology studies. To assess covariate effects on the gaps between consecutive recurrent events, the Cox proportional hazards model is frequently employed in data analysis. The validity of statistical inference, however, depends on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics